Table 2. Univariable Cox regression analysis for PFS in EC patients treated with ICI.
AMolecular subtyping n=434 patients, excluding 3 with POLE. B Pre-treatment abdominal CT scans were available for 500 patients. Reference alludes to reference group for the analysis. BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; CPNH/TP53abn, copy number-high/TP53abnormal; CNL/NSMP, copy number-low/no specific molecular profile; MSI-H, microsatellite instability high; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue.
| Baseline characteristic | Variables | Univariable HR (95% CI) | p value |
|---|---|---|---|
| BMI (kg/m 2 ) | Normal (reference) | 1 | |
| Overweight | 0.71 (0.55 – 0.93) | 0.011 | |
| Obese | 0.61 (0.47 – 0.77) | <0.0001 | |
| Age (years) | 1 (0.99 – 1.01) | 0.83 | |
| Self-reported race | White (reference) | 1 | |
| Asian | 1.14 (0.79 – 1.65) | 0.47 | |
| Black | 1.21 (0.92 – 1.6) | 0.18 | |
| Other | 0.83 (0.57 – 1.22) | 0.35 | |
| Histology | Endometrioid low grade (reference) | 1 | |
| Endometrioid high grade | 1.59 (1.12 – 2.26) | 0.01 | |
| Serous | 1.88 (1.4 – 2.53) | < 0.0001 | |
| Mixed/high-grade NOS | 2.07 (1.48 – 2.9) | < 0.0001 | |
| Carcinosarcoma | 2.53 (1.79 – 3.6) | < 0.0001 | |
| Clear cell | 1.46 (0.86 – 2.47) | 0.16 | |
| Un-/dedifferentiated | 1.76 (0.93 – 3.3) | 0.08 | |
| Checkpoint inhibitor | Pembrolizumab (reference) | 1 | |
| Durvalumab | 2.26 (1.73 –2.94) | <0.0001 | |
| Nivolumab | 1.63 (0.95 – 2.79) | 0.08 | |
| Other | 0.22 (0.06 – 0.88) | 0.03 | |
| Combination therapies | Lenvatinib/pembrolizumab (reference) | 1 | |
| Tremelimumab/durvalumab | 2.22 (1.54 – 3.2) | <0.0001 | |
| ICI alone | 0.71 (0.57 – 0.9) | 0.005 | |
| Other combination | 2.14 (1.1 – 4.17) | 0.03 | |
| ECOG Performance Status | 0 (reference) | 1 | |
| 1 | 1.24 (1 – 1.52) | 0.04 | |
| 2–3 | 4.28 (2.62 – 6.99) | < 0.0001 | |
| Stage at diagnosis | 1,2 (reference) | 1 | |
| 3,4 | 1.28 (1.04 – 1.58) | 0.02 | |
| Previous lines of therapy | 0 (reference) | 1 | |
| 1 | 1.9 (1.14 – 3.17) | 0.013 | |
| 2 | 2.48 (1.47 – 4.2) | 0.0007 | |
| ≥3 | 3.41 (1.96 – 5.92) | <0.0001 | |
| Previous pelvic radiotherapy | No (reference) | 1 | |
| Yes | 0.87 (0.71 – 1.06) | 0.17 | |
| Molecular Subtype A | MSI-H | 1 | |
| CN-H/TP53abn | 3.05 (2.19 – 4.25) | < 0.0001 | |
| CN-L/NSMP | 2.91 (1.98 – 4.27) | < 0.0001 | |
| VAT (cm 2 ) B | Low (≤112 cm2) (reference) | 1 | |
| High (>112 cm2) | 0.69 (0.56 – 0.85) | 0.0004 | |
| SAT (cm 2 ) B | Low (≤270 cm2) (reference) | 1 | |
| High (>270 cm2) | 0.82 (0.67 – 1.01) | 0.062 |